In 1971, Krugman demonstrated that inoculation of boiled serum obtained from an HBsAg carrier prevented subsequent hepatitis B infection. At that time, as now, all attempts to propagate the virus in cell culture and prepare a vaccine in the conventional way had failed, meaning that Krugman's experiments formed the basis for the development of an HB vaccine made from the plasma of chronic HBsAG carriers. Hepatitis B vaccines were developed by several groups, and the efficacy, immunogenicity and safety of the vaccines were demonstrated in large clinical studies, such as the famous double-blind trials conducted on New York homosexuals by Szmuness and on French dialysis patients and personnel by Maupas. In 1981, the vaccine was licensed in the U.S.A., and some months later in most European countries. The results of the initial studies have since been confirmed by the vaccination of about three million people to date (for an overview see reference 1). In a healthy adult population, more than 90% of the vaccinees develop the protective antibody, anti-HBs, after three vaccinations; protection is achieved with a vaccine efficacy of about 90%. Side-effects are negligible. In none of the cases have hepatitis B, hepatitis non-A non-B or the acquired immunodeficiency syndrome (AIDS) been transmitted by the vaccine; the susceptibility of LAV/ HTLV III is such that it would be readily inactivated by each of the inactivation steps used in vaccine preparation. With the exception of allergies to formaldehyde, which is used for inactivation, and to thimerosal, which is added as a bacteriostaticum, there are no contraindications for the use of the HB vaccine. Gravidity is not a contra-indication; since the HB vaccine is not a live vaccine, there is no risk of embryopathy. On the contrary, the vaccination is strongly indicated for pregnant women at a high risk of contracting hepatitis B, e.g. nurses working in dialysis units or infection wards, because newborns run a high risk of becoming chronic carriers of HBsAg when mothers are HBsAg-positive at the time of birth. Newborns tolerate the vaccine very well. Although immediate passive immunization with HB immunoglobulin provides important partial protection for the babies of HBsAg-carrier mothers, passive-active immunization is the most effective measure. The feasibility of such passive-active immunization has been demonstrated in newborns as well as in adults; no interference of the passively transferred immunoglobulins with the developing "active" immunity has been observed. Immediate protection as well as long-term immunity is provided; this is especially important for the newborns of HBsAg-positive mothers, most of whom are chronic carriers and can also infect their children later. Passive-active immunization is also recommended for those who need immediate protection, e.g. persons working in high risk surroundings such as dialysis units and infection wards or persons in contact with HBsAg carriers. Although the vaccine works well in healthy children and adults, vaccination of immunocompromised persons, especially dialysis patients, is still a problem. These patients are at an increased risk of contracting hepatitis B, and if infected, very often become chronic carriers as a consequence of their impaired immune systems. Protection against hepatitis B is therefore very important for this group; unfortunately, the response to the HB vaccination is rather poor in these patients. Only 50%-70% develop specific antibodies, and the resultant anti-HBs levels are low. Although multiple injections show better results, immune responses are still significantly lower than in healthy persons, and the responses in transplant patients and children with hematologic malignancies are even worse. Despite these less than ideal responses in some groups of individuals, vaccination against HB is now an accepted preventive 6aeasure for people at risk of infection. Some uncertainty, however, still exists about the persistence of anti-HBs after vaccination, and about the need for and the timing of revaccination. Whereas earlier studies lead to the belief that anti-HBs levels would remain higher than 10 IU/I (considered to be the minimal protective level) for about five years after completion of the vaccination, longterm follow-up studies have shown that in some individuals, anti-HBs levels fall below this value or even disappear much earlier. Recently, a close correlation was demonstrated between the peak anti-HBs concentration after vaccination and the persistence of specific antibodies; thus, a quantitative determination of antiHBs after the basic immunization allows a fairly accurate prediction of the length of protection and consequently of the time for revaccination (2). Whether there is protection below the 10 IU/ml level is still a matter for debate. In several studies, hepatitis B infections have been observed in vaccinees whose anti-HBs levels had decreased to low (below 50 IU/1) or zero. However, in otherwise healthy individuals only subclinical or mild infections have been seen, resulting in most cases in seroconversion to anti-HBc without HBsAg being present and without liver enzymes being elevated, an argument for some protective effects of the vaccination even when measurable anti-HBs has disappeared (3). Although the vaccine presently in use is safe and effective, it has the major drawback of being expensive because the costs of the starting material, human plasma, and the extensive purification procedures are high. This seriously limits the use of this vaccine, especially in the
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